ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1266

Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen

Nina P. Sundlisater1, Siri Lillegraven1, Inge C Olsen1, Anna-Birgitte Aga1, Till Uhlig1, Hilde B. Hammer2, D van der Heijde1,3, Tore K. Kvien1, Espen Haavardsholm1 and ARCTIC study group, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Early Rheumatoid Arthritis, prognostic factors and radiography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: With implementation of tight control strategies and defined treatment targets in rheumatoid arthritis (RA) care, a majority of early RA patients may reach remission and traditional predictors of joint damage might no longer be present. The aim of our study was to identify baseline parameters predictive of 2-year radiographic progression in an early RA population treated by a semi-personalized treat-to-target strategy.

Methods: DMARD naive RA patients with <2 years from first patient reported swollen joint, who fulfilled the 2010 ACR/EULAR criteria, were included in the ARCTIC study. Patients were followed for 24 months with treatment according to an aggressive algorithm targeting clinical remission (DAS <1.6 and SJC44=0), and in half the patients an additional target was imaging remission (absence of ultrasound PD signal). Patients with risk factors for progressive joint destruction (ACPA or RF positive with baseline erosions, or MRI bone marrow edema) could be escalated more rapidly from MTX monotherapy to biologics. Radiographs were scored by two readers using the van der Heijde-Sharp score (vdHSs), with cut-off 1 unit or more change/year to be classified as progression. Potential baseline predictors were analyzed for collinearity, and remaining variables assessed by univariate logistic regression. Variables with univariate p<0.25 were included in the multivariate model building, and p<0.05 was required to remain in the model.

Results: Mean [SD] disease duration for the 222 patients was 7.2 [5.4] months, and mean DAS based on 44 joints was 3.5 [1.2]. 72% were RF and 82% ACPA positive. 41% had radiographic progression at 24 months, while DAS remission was reached by 68%. In 16% treatment was escalated more rapidly due to baseline risk factors. In univariate models, gender, age, smoking, RF, tender joints, 44 SJC, ESR, total GS-score, total PD-score and vdHSs at baseline had p<0.25, while BMI, disease duration<3months, ACPA and patient global had p>0.25. In the multivariate model, RF positivity (OR 2.27, p=0.022), total vdHSs (OR 1.08, p=0.017) and ultrasound GS score (OR 1.03 per unit, p=0.019) were independent baseline predictors of radiographic progression at 24 months (table). Ultrasound PD was not an independent predictor in secondary models built without GS or in separate models for the two strategy arms, neither as a continuous nor dichotomized variable according to the mean (9.8) and median (7) baseline score.

Table: Multivariate model for baseline predictors of radiographic progression at 24 months (corrected for age and gender). Radiographic progression occurred in 92/222.

Univariate

Multivariate

Baseline variables

OR [CI]

P-value

OR [CI]

P-value

US GS-score (0-96)

1.03 [1.01, 1.05]

0.005

1.03 [1.00, 1.05]

0.019

RF positivity (IgM/IgA)

1.78 [0.96, 3.29]

0.07

2.27 [1.13, 4.57]

0.022

Total van der Heijde Sharp score

1.11 [1.06, 1.17]

<0.001

1.08 [1.01, 1.14]

0.017

Conclusion: RF positivity, radiographic joint damage and ultrasound gray-scale score were independent baseline predictors of joint damage in early RA patients treated according to an aggressive treatment regimen aiming for remission. This indicates that further individualization of treatment based on risk factors might be needed to optimize disease outcomes, also in treat-to-target strategies.


Disclosure: N. P. Sundlisater, None; S. Lillegraven, None; I. C. Olsen, None; A. B. Aga, None; T. Uhlig, None; H. B. Hammer, None; D. van der Heijde, Imaging Rheumatology by Director, 9; T. K. Kvien, Biogen, BMS, Boehringer, 5; E. Haavardsholm, Pfizer, MSD, UCB, AbbVie, Roche, 2.

To cite this abstract in AMA style:

Sundlisater NP, Lillegraven S, Olsen IC, Aga AB, Uhlig T, Hammer HB, van der Heijde D, Kvien TK, Haavardsholm E. Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/predictors-of-radiographic-progression-in-early-rheumatoid-arthritis-patients-treated-by-an-aggressive-treat-to-target-regimen/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-radiographic-progression-in-early-rheumatoid-arthritis-patients-treated-by-an-aggressive-treat-to-target-regimen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology